SUDA Announces Entitlement Offer to Raise $3.56 Million Capital

  • Jul 03, 2020 AEST
  • Team Kalkine

In a latest update, SUDA Pharmaceuticals Ltd (ASX:SUD) has announced a non-renounceable entitlement offer of fully paid ordinary shares to raise ~$3.56 million.  SUDA is also offering its shareholders 1 option for every 3 New Shares issued with an expiry date of 31 July 2022 and an exercise price of $0.05.  

SUDA has also provided the following details with regards to the Entitlement Offer:

  • Offer price of $0.025 per share
  • Offer price represents a 34 per cent discount to 15-day VWAP
  • The proceeds of the Entitlement Offer will be used towards the development of SUDA’s Anagrelide and the remaining OroMist® assets, the potential acquisition and development of new assets, and general working capital.

SUDA’s stock traded at $0.036 as at 12:04 PM AEST.


The website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


Want to get exclusive insights into the star stock of the year? Gold stocks stood solid and ensured a safety net for investors.

Click now to access our report on Gold Stocks to understand how the rise in gold prices propelled the ASX-listed gold stocks, and many emerged as the star performer of the year.

Inside this report, you shall discover

How the price trends of gold have got it where it is With the rallying gold prices and the record-buying from Central Banks, the gold spot rose from $1,655.14 (low in December 2018) to $2,322.26 (high in August 2019). A promising return of over 40 percent was seen in the year 2019. Get exclusive insights into how the trends set the foundation for the performance and how Gold stocks seem to be a safe bet when you look back.

Which stocks you should have been looking at: Find out which stocks delivered promising returns to investors. Gold stocks such as Gold Road Resources Limited (ASX: GOR), Kirkland Lake Limited (ASX: KLA) Newcrest Mining Limited (ASX: NCM) delivered better returns against the S&P Commodity Producers Gold Total Return Index.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK